ArticleAdvances in therapy2026

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Justin M Watts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.